The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22-65
SponsorUniversity Hospital of North Norway

About this trial

The present project aims to assess the neurocognitive impact of a two-week once-a-day regimen of intermittent theta burst stimulation (iTBS) compared to sham iTBS, when targeting the left dorsolateral prefrontal cortex (LDLPFC) in clinically depressed outpatients. The study investigates the relationships between changes in cerebral measures and cognitive performance on an N-back task in relation to the antidepressive effect following iTBS.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients must meet the diagnostic criteria of at least a moderate depression

The duration of the current depressive episode must have lasted more than 2 weeks but less than 2 years

Drug therapy must have been stable for the last three weeks prior to the first treatment day with iTBS

Patients must volunteer to provide informed consent, be able to follow the treatment schedule and have a satisfactory safety screening for iTBS and MRI

Disqualifiers

The current depressive episode is in the mild range

The current episode fulfills the criteria for a major depressive episode requiring inpatient treatment and/or electroconvulsive therapy,

The current depressive episode is clearly triggered by grief or a recent major stressful life event

Bipolar disorder

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intermittent Theta Burst Stimulation

    Device

    Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Intermittent Theta Burst StimulationActive comparator 1 intervention
Group B: Sham Intermittent Theta Burst StimulationPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Data from magnetic resonance imaging - white matter integrity

Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in anatomical measures of cerebral white matter integrity quantified by fractional anisotropy measured by diffusion tensor imaging (DTI) obtained from magnetic resonance imaging (MRI).

Time frame
Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days
2

Data from magnetic resonance imaging - cortical thickness

Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in anatomical measures of thickness in cerebral gray matter thickness quantified by T1-weighted magnetic resonance imaging (MRI).

Time frame
Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days
3

Data from magnetic resonance imaging - cerebral activity

Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in cerebral activity quantified by blood-oxygen-level-dependent (BOLD) responses measured by functional resonance imaging (fMRI).

Time frame
Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days

Secondary outcomes

1

Performance on a N-back cognitive test

Differences between groups when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation in behavioral performance on a cognitive task measuring working memory and executive performance when comparing intermittent theta burst stimulation versus sham intermittent theta burst stimulation.

Time frame
Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital of North Norway

Lead sponsor

UiT The Arctic University of Norway

Collaborator